Evonik stock rises 0.87 percent as takeover interest supports shares

Published on 10/07/2026 at 14:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock was trading at EUR 20.96 on October 7, 2026, while Berenberg raised its target to EUR 20. Q2 adjusted EBITDA rose 24 percent to EUR 630 million.

Buntes Pop-Art-Comic im Lichtenstein-Stil mit Laborwissenschaftler und farbig brodelnden Reagenzgläsern — Evonik Industries DE000EVNK013 als bunter Pop-Art-Comic eines begeisterten Laborwissenschaftlers mit farbigen Reagenzgläsern, Illustration mit AI erstellt.

Evonik stock was trading at EUR 20.96 on Xetra on October 7, 2026, up 0.87 percent from the previous close and 0.38 percent below its 52-week high of EUR 21.04. The market is weighing takeover speculation alongside a stronger second-quarter operating performance.

BASF interest keeps valuation in view

According to EQS News on September 25, 2026, Evonik confirmed that BASF had submitted a non-binding approach regarding a potential voluntary public takeover offer for all shares.

The takeover angle has already influenced analyst thinking. Investing.com reported on October 5, 2026, that Berenberg upgraded Evonik from Sell to Hold and raised its price target from EUR 15.50 to EUR 20. The move linked the revised view to BASF's takeover interest, while also highlighting pressure in methionine and other businesses.

Q2 earnings strengthen the case

Evonik's Q2 2026 adjusted EBITDA rose 24 percent year over year to EUR 630 million, according to the company's earnings call transcript published by Yahoo Finance. Management said higher volumes and higher prices each contributed 7 percent to the increase.

The same transcript showed adjusted EBITDA of EUR 1.1 billion for the first half of 2026 and described the upgraded full-year outlook as requiring another EUR 1 billion in the second half to reach its midpoint. That comparison matters because the earnings recovery is running ahead of the weak industrial backdrop that had shaped earlier analyst caution.

Q3 date sets the next checkpoint

Evonik's investor-relations calendar schedules publication of the Q3 2026 quarterly statement for November 3, 2026. The next report will test whether the Q2 combination of pricing, volumes and cost savings is continuing into the second half.

For investors, the key tension is visible in the figures: the stock is close to its yearly high, while Berenberg's EUR 20 target sits EUR 0.96 below the October 7 price. The takeover narrative supports the valuation, but operating momentum still has to withstand normalization in selected businesses.

Evonik stock stays near yearly high

Evonik stock was last trading at EUR 20.96 on Xetra on October 7, 2026 at 1:49 p.m. CEST. Its 52-week range was EUR 12.49 to EUR 21.04, with a market capitalization of EUR 9.8 billion and volume of 381,242 shares.